According to reports, the impact of the COVID-19 vaccine by Pfizer-BioNTech vaccine declines faster than that of the AstraZeneca jab.
In a study published on Thursday, August 19, researchers at Oxford University stated that "Two doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infections, but this declines faster compared with two doses of Oxford-AstraZeneca,"
Meanwhile, the study which has not been peer-reviewed is based on the results of a survey by Britain's Office for National Statistics that carried out PCR tests from December last year to this month on randomly selected households.
On the other hand, earlier on August 16, Pfizer and BioNTech stated that they have submitted early-stage clinical trial data to the Food and Drug Administration as part of their U.S. application seeking authorization of a vaccine booster for the coronavirus for everyone 16 and older.
According to reports, in the phase one trial, a booster dose of the vaccine generated “significantly higher neutralizing antibodies” against the original strain of the coronavirus as well as the beta and delta variants. Moreover, participants in the trial received a third shot of the two-dose vaccine about eight to nine months after receiving their second shot. In addition, the companies informed that late-stage trial results evaluating the third dose are expected shortly and will also be submitted to the FDA and other regulatory authorities worldwide.
ALSO READ: COVID-19 vaccines Pfizer, AstraZeneca likely to need booster doses
Share
Tweet
